Symbols

Symbols

PODD

PODD

Insulet Q3 2025 Results Exceed Expectations, Omnipod Expansion, and Upgraded Guidance Drive Strong Valuation

Friday Nov 07, 2025

Insulet: Canaccord Genuity Raises PT to $428, Maintains Buy Rating

Insulet Q3 Earnings: Revenue Up 29.9% to $706.3M, EPS at $1.24

Insulet: RBC Capital Keeps Outperform Rating, PT Raised to $370

Wells Fargo Raises Insulet PT to $360, Maintains Overweight Rating

Insulet's Strong Q3 and Raised Outlook: A Shift in Investment Narrative?

UBS Raises Insulet PT to $355, Maintains Neutral Rating

Insulet: Truist Securities Raises Buy Rating, PT to $390 from $365

Insulet Corp (PODD) December 2026 Options: A Closer Look at the PODD Put and Call Contracts

Insulet: Barclays Maintains Equal-Weight, Raises PT to $316 from $301

Thursday Nov 06, 2025

Insulet Corp. Q3 Income Surges to $87.6M, Revenue Rises 29.9%

Insulet: Jefferies maintains Buy, raises PT to $400 from $375.

Insulet's 15min chart sees Bollinger Bands expanding upward, KDJ golden cross detected.

Insulet Reports Q3 Earnings: Revenue Up 29.9%, EPS Surpasses Expectations

Insulet Reports Q3 Profit Surge, Revenue Up 30% YoY.

Insulet shares surge 6.65% premarket after Q3 results beat estimates, revenue jumps 29.9% and guidance raised.

Wednesday Nov 05, 2025

Insulet's 15min chart triggered Bollinger Bands Narrowing, KDJ Death Cross detected.

Insulet: Barclays Maintains Equal-Weight, Raises PT to $301 from $300

Insulet's 15min chart: MACD Death Cross, KDJ Death Cross signals decline.

Insulet, Uber, and Apollo Global Management Highlighted in CNBC's 'Final Trades'